Hyperacute lung cancer cell vaccine (NewLink Genetics Corporation)

N/A

Report date: 2023/02/18 19:47:38

Base Information

Drug NameHyperacute lung cancer cell vaccine (NewLink Genetics Corporation)
Drug Alias Name超急性肺癌细胞疫苗-NewLink Genetics
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNewlink Genetics Co
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNewlink Genetics Co
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A